4-Chlor-1-hydroxy-2,2,6,6-tetramethyl-piperidin | 1796-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Chlor-1-hydroxy-2,2,6,6-tetramethyl-piperidin
• 英文别名: 4-chloro-2,2,6,6-tetramethyl-piperidin-1-ol；4-Chloro-1-hydroxy-2,2,6,6-tetramethylpiperidine
• CAS: 1796-16-3
• 化学式: C₉H₁₈ClNO
• 分子量: 191.701
• InChiKey: URDZAZJWDUZUSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Drug Resistance Reversal In Neoplastic Disease
  申请人：Patil Ghanshyam

  公开号：US20080200405A1

  公开（公告）日：2008-08-21

  The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.

  本发明涉及用于阻止或逆转肿瘤性疾病化疗耐药效应的化合物、组合物和方法。具体描述了羟胺的使用。
• [EN] SULFONATED NITROPHENOLS AS POLYMERIZATION INHIBITORS<br/>[FR] NITROPHÉNOLS SULFONÉS EN TANT QU'INHIBITEURS DE LA POLYMÉRISATION
  申请人：CHEMTURA CORP

  公开号：WO2006036426A1

  公开（公告）日：2006-04-06

  Disclosed herein is a method for inhibiting and retarding the premature polymerization and the polymer growth of ethylenically unsaturated monomers comprising adding to said monomers an effective amount of at least one inhibitor that is a sulfonated nitrophenol of the formula: (I) wherein: R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkyl, NO2, and S03H, provided that at least one of R,, R2, and R3 is NO2 and at least one of R1, R2, and R3 is SO3H. In a preferred embodiment, at least one additional inhibitor selected from the group consisting of nitroxyl compounds, nitrosoanilines, nitrophenols, amines, and mixtures thereof is also added.

  本文揭示了一种抑制和延缓乙烯基不饱和单体的聚合物的过早聚合和聚合物生长的方法，包括向所述单体中添加至少一种抑制剂，其为公式（I）的磺化硝基苯酚的有效量：其中：R1、R2和R3是独立选择自氢、烷基、NO2和S03H的群组，前提是R1、R2和R3中至少有一个是 ，且R1、R2和R3中至少有一个是SO3H。在优选实施例中，还添加了至少一种来自亚硝基化合物、亚硝基苯胺、硝基苯酚、胺和它们的混合物的附加抑制剂。
• Blends of quinone alkide and nitroxyl compounds and polymerization inhibitors
  申请人：——

  公开号：US20040010159A1

  公开（公告）日：2004-01-15

  Disclosed herein is a method for inhibiting the premature polymerization of ethylenically unsaturated monomers comprising adding to said monomers an effective amount of: A) at least one nitroxyl compound, and B) at least one quinone alkide compound having an electron-withdrawing group at the 7-position. Additionally, a composition is disclosed that comprises: A) at least one nitroxyl compound, and B) at least one quinone alkide compound having an electron-withdrawing group at the 7-position.

  本公开涉及一种抑制乙烯基不饱和单体的过早聚合的方法，包括向所述单体中添加有效量的：A) 至少一种亚硝基化合物，和B) 在7位具有电子吸引基团的至少一种醌烯化合物。此外，还公开了一种包括：A) 至少一种亚硝基化合物，和B) 在7位具有电子吸引基团的至少一种醌烯化合物的组合物。
• [EN] SULFONATED PHENOLS WITH NITROPHENOLS AS POLYMERIZATION INHIBITORS<br/>[FR] PHENOLS SULFONES AVEC NITROPHENOLS COMME INHIBITEURS DE POLYMERISATION
  申请人：CHEMTURA CORP

  公开号：WO2006036274A1

  公开（公告）日：2006-04-06

  Disclosed herein is a method for inhibiting the premature polymerization and the polymer growth of ethylenically unsaturated monomers comprising adding to said monomers an effective amount of a combination of (A) at least one inhibitor that is a sulfonated phenol of the formula (I): wherein (1) R2 is selected from the group consisting of hydrogen and hydrocarbyl; and (2) R1 and R3 are independently selected from the group consisting of hydrogen and SO3H, provided that at least one of R1 and R3 is SO3H; (B) at least one inhibitor that is a nitrophenol; and, optionally, (C) an inhibitor selected from the group consisting of nitroxyl compounds and nitrosoanilines; and (D) an amine.

  本文公开了一种抑制乙烯基不饱和单体的过早聚合和聚合生长的方法，包括向该单体中添加以下组合物的有效量：（A）至少一种为公式（I）的磺化酚抑制剂，其中（1）R2选自氢和烃基组成的群体；（2）R1和R3独立地选自氢和SO3H组成的群体，但其中至少一个为SO3H；（B）至少一种为硝基酚的抑制剂；以及可选地，（C）从硝基氧化物化合物和硝基苯胺组成的群体中选择的抑制剂；和（D）胺。
• HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE
  申请人：Patil Ghanshyam

  公开号：US20080280890A1

  公开（公告）日：2008-11-13

  The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.

  本公开提供了包括式I或II的羟胺化合物、制药组合物以及它们的使用方法。该方法利用羟胺化合物及/或其制药组合物治疗血管生成、肝炎、补体介导的病理、色斑介导的病理、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病，并抑制补体激活。